ResearcherMayo ClinicActive in the last 2 years
Niv Pencovich
Matched on ORCID iD 0000-0002-0049-0295; OpenAlex author ID A5102762038. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper
Papers 7
- Transcriptomics of Upper Gastrointestinal Fluids Can Diagnose Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2026.101776↗
- Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Ther… Last author DOI 10.1245/s10434-025-17433-3↗
- ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing… First author DOI 10.1245/s10434-025-17536-x↗
- Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection. Last author DOI 10.3390/jcm14155538↗
- Should we resect distant metastases?-reconsidering radical resection of pancreatic cancer with liver metastases. Co-author DOI 10.21037/hbsn-24-322↗
- Perioperative Platelet Count Ratio Predicts Long-Term Survival after Left Pancreatectomy and Splenectomy for Pancreatic Adenocarcinoma. Last author DOI 10.3390/jcm13041050↗
- Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center. Co-author DOI 10.1186/s12957-020-01828-5↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ido Nachmany · 6 shared papers, 2020–2026 · strength 1.51
- Paper Should we resect distant metastases?-reconsidering radical resection of pancreatic cancer with liver metastases. DOI 10.21037/hbsn-24-322↗
- Paper Transcriptomics of Upper Gastrointestinal Fluids Can Diagnose Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.jcmgh.2026.101776↗
- Paper Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical… DOI 10.3390/jcm14155538↗
- Arielle Jacover · 3 shared papers, 2025 · strength 1.00
- Paper ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline… DOI 10.1245/s10434-025-17536-x↗
- Paper Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical… DOI 10.3390/jcm14155538↗
- Paper Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancre… DOI 10.1245/s10434-025-17433-3↗
- Ron Pery · 4 shared papers, 2024–2026 · strength 0.94
- Paper Transcriptomics of Upper Gastrointestinal Fluids Can Diagnose Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.jcmgh.2026.101776↗
- Paper Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical… DOI 10.3390/jcm14155538↗
- Paper Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancre… DOI 10.1245/s10434-025-17433-3↗
- Nedaa Mahamid · 2 shared papers, 2025 · strength 0.46
- Paper Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical… DOI 10.3390/jcm14155538↗
- Paper Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancre… DOI 10.1245/s10434-025-17433-3↗
- Talia Golan · 2 shared papers, 2025 · strength 0.46
- Paper Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical… DOI 10.3390/jcm14155538↗
- Paper Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancre… DOI 10.1245/s10434-025-17433-3↗
- Tal Barkai · 1 shared paper, 2026 · strength 0.28
- Hallbera Gudmundsdottir · 1 shared paper, 2024 · strength 0.20
- Boaz Sagie · 1 shared paper, 2020 · strength 0.11
- Lior Orbach · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.